1alpha,25-Dihydroxy-2beta-(3-hydroxypropoxy)vitamin D(3) (ED-71), an analog of active
vitamin D(3),
1alpha,25-dihydroxyvitamin D(3) [
1,25(OH)(2)D(3)], possesses a hydroxypropoxy substituent at the 2beta-position of
1,25(OH)(2)D(3).
ED-71 has potent
biological effects on bone and is currently under phase III clinical studies for
bone fracture prevention. It is well-known that the synthesis and secretion of
parathyroid hormone (PTH) is regulated by
1,25(OH)(2)D(3). Interestingly, during clinical development of
ED-71, serum intact PTH in osteoporotic patients did not change significantly upon treatment with
ED-71. The reason remains unclear, however. Brown et al. reported that 3-epi-1,25(OH)(2)D(3), an epimer of
1,25(OH)(2)D(3) at the 3-position, shows equipotent and prolonged activity compared to
1,25(OH)(2)D(3) at suppressing PTH secretion. Since
ED-71 has a bulky hydroxypropoxy substituent at the 2-position, epimerization at the adjacent and sterically hindered 3-position might be prevented, which may account for its weak potency in PTH suppression observed in clinical studies. We have significant interest in
ED-71 epimerization at the 3-position and the
biological potency of 3-epi-ED-71 in suppressing PTH secretion. In the present studies, synthesis of 3-epi-ED-71 and investigations of in vitro suppression of PTH using bovine parathyroid cells are described. The inhibitory potency of
vitamin D(3) analogs were found to be
1,25(OH)(2)D(3)>
ED-71> or =3-epi-
1,25(OH)(2)D(3)>>3-epi-
ED-71.
ED-71 and 3-epi-ED-71 showed weak activity towards PTH suppression in our assays.